Aug 2026
Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine.
O. Launay, Emilie Piat, O. Bonduelle et al.
· Journal of Infectious Diseas... · 0 citations